AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03019211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT03019211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT06388525 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography
Study NCT03675022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
Study NCT01726192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a femoral catheter with the hydrolocalization technique
Description: Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
Study NCT01726192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a femoral neurostimulating catheter
Study NCT01923727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [89Zr]Df-IAB2M
Description: A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
Study NCT02049073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
Study NCT02049073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 32 mg or 64 mg pill administered orally once
Study NCT02628054 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vaccine
Description: Typhoid Vaccine injection given 7 days apart
Study NCT02628054 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection given 7 days apart
Study NCT01422889 — intervention group
Intervention type: DEVICE
Intervention: ION™ Coronary Stent System
Description: This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
Study NCT03859596 — intervention group
Intervention type: PROCEDURE
Intervention: MGB/OAGB
Description: BARIATRIC PROCEDURE INVOLVED CREATION OF SLENDER GASTRIC POUCH OF 12-15CM IN LENGTH AND BILIO-PANCREATIC LIMB OF 150-200 CM
Study NCT01591135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus 5-fluorouracil
Description: 5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
Study NCT01591135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin plus 5-fluorouracil
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
Study NCT01591135 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Study NCT01591135 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Study NCT00664768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neocate Infant
Description: minimum of 8 fl. oz daily
Study NCT00664768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: new Neocate
Description: minimum of 8 fl oz daily
Study NCT00916084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Tongue Appliance
Description: A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.
Study NCT00916084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Face Mask
Description: An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
Study NCT01747616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological saline solution
Description: 1 drop as placebo in the other eye not receiving the medical device
Study NCT03035149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Management Program
Description: Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
Study NCT00669149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel + aspirin
Study NCT00669149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin + clopidogrel + aspirin
Study NCT00669149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin + clopidogrel + aspirin
Study NCT01907490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ha44 Gel
Description: Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
Study NCT03142139 — intervention group
Intervention type: BIOLOGICAL
Intervention: RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib
Description: Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:~* timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age~* delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age.
Study NCT03142139 — intervention group
Intervention type: BIOLOGICAL
Intervention: RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib
Description: Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:~* timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age~* delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age.
Study NCT03142139 — intervention group
Intervention type: BIOLOGICAL
Intervention: RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated
Description: • Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated.
Study NCT05386459 — intervention group
Intervention type: DRUG
Intervention: Interferon Gamma
Description: injection form
Study NCT02560922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (CST)
Description: The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
Study NCT02183324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BI 1356 BS
Study NCT02183324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BI 1356 BS
Study NCT02183324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BI 1356 BS
Study NCT02183324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02097472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PATH-wSP
Description: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Study NCT02097472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: 1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Study NCT02097472 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: 1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Study NCT02097472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavac
Description: Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection.
Study NCT02097472 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentavac
Description: Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection.
Study NCT02097472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% Sodium Chloride Injection, USP
Study NCT02097472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.9% Sodium Chloride Injection, USP
Study NCT02097472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 0.9% Sodium Chloride Injection, USP
Study NCT01844804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06438179
Description: Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
Study NCT01844804 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
Study NCT00249457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
Study NCT02801448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: sulforaphane-containing broccoli sprout extracts
Study NCT02801448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrine-based placebo without sulforaphane
Study NCT00194818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol (mesalamine)
Description: Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
Study NCT00580359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1, capecitabine
Description: S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
Study NCT01102777 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: automated internet-mediated walking program
Description: intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
Study NCT01102777 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
Study NCT01121900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours.
Study NCT01121900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period.
Study NCT03601247 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: silicone gel
Description: Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day
Study NCT00162435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT03440281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine artery doppler
Description: Uterine artery Doppler pulsatility indices
Study NCT03440281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal serum homocysteine estimation
Study NCT00485485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 400 mg by mouth daily
Study NCT00485485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m\^2 by vein (IV) over 1 hour every 3 weeks
Study NCT05853250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki/manual therapy
Description: Reiki is delivered by gentle hand placement either on or slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 minutes and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (\~ 3 minutes to each body part). Manual therapy techniques include light effleurage to head and feet (for 5 minutes; \~ 2.5 minutes to each body part) by the Reiki practitioner who delivered the Reiki therapy.
Study NCT04137380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab - IV
Description: Administered IV
Study NCT04137380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab - SC
Description: Administered SC
Study NCT04137380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV
Study NCT04137380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study NCT01802346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Consume a low-calorie diet
Study NCT01802346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nutritional support
Description: Receive dietary advice
Study NCT01802346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01802346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02724137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit®
Description: Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.
Study NCT02724137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Rehab
Description: Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
Study NCT02724137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Rehab
Description: Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
Study NCT01872689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
Study NCT01872689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
Study NCT01872689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
Study NCT01872689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
Study NCT01872689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
Study NCT05615298 — intervention group
Intervention type: RADIATION
Intervention: Mammography
Description: FFDM (Full-Field Digital mammography)
Study NCT02592330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft
Description: Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
Study NCT02592330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultivation of Limbal epithelial cells into a graft
Description: A graft is manufactured for transplant
Study NCT02592330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CALEC Transplant
Description: Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.
Study NCT04117932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
Study NCT03912857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd
Study NCT01194960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
Study NCT01194960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
Study NCT01194960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TroVax
Description: Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37